Post-ASH January 22, 2022 Myeloma Round Table image

Post-ASH January 22, 2022 Myeloma Round Table

Jan 22, 2022
12:00PM - 01:30PM EST
Online Event
Overview

We will feature some interesting studies from the annual American Society of Hematology (ASH) meeting with the authors on a Myeloma Crowd Round Table (MCRT) webcast on Saturday, January 22, 2022 at noon Eastern.

Our speakers will discuss issues including precursor conditions, the myeloma microenvironment, applications of minimal residual testing (MRD), and chromosome one abnormalities.  All will be available for an extensive question-and-answer session on any issue in the second half of the 90 minute program.

 

Highlights
Agenda
12:00 PM
Post-ASH MCRT
Introduction and Welcome
12:05 PM
Post-ASH MCRT
Introduction and Welcome
12:50 PM
Post-ASH MCRT
Audience Questions
Speakers & Moderators
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Healthtree contact Greg Brozeit

Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.
Healthtree contact Timothy Schmidt, MD

Timothy Schmidt, MD

Dr. Timothy Schmidt is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine at the University of Wisconsin-Madison. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. His clinical interest is in management of hematological malignancies, including the use of bone marrow transplantation and CAR-T cell therapy. In his clinic, he specializes in caring for patients with multiple myeloma and other plasma cell disorders including monoclonal gammopathies and amyloidosis. Dr. Schmidt’s research focuses on improving outcomes for patients with multiple myeloma. He is involved in the development and conduct of early phase and cooperative group clinical trials for patients with plasma cell disorders. Dr. Schmidt is interested in differentiating patterns of disease biology that lead to variable outcomes among patients with multiple myeloma. Through outcomes research and scientific collaborations with laboratory-based researchers, Dr. Schmidt hopes to translate these findings into clinical trials that aim to clarify how treatment may be tailored for individual patients to improve survival and reduce toxicity.
Healthtree contact Sigrun Thorsteinsdottir, MD, PhD

Sigrun Thorsteinsdottir, MD, PhD

Dr. Thorsteinsdotter is a postdoctoral fellow from the University of Iceland currently working at the Rigshospitalet in Copenhagen, Denmark.
Healthtree contact Francesco Maura, MD

Francesco Maura, MD

Dr. Maura is assistant professor and co-director of the Myeloma Genomic Lab at the Sylvester Cancer Center at the University of Miami, Florida. His research activity is focused on the genomic mechanisms and driver events involved in the pathogenesis and progression of lymphoproliferative disorders. His main focus has been on multiple myeloma and its precursors. The other area of interest is the understanding of the key mechanisms involved in cancer resistance to novel drugs, including immunotherapy.